Cadonilimab (a PD-1/CTLA-4 Bispecific Antibody) plus Neoadjuvant Chemotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma: A Phase II Clinical Trial
Cadonilimab plus neoadjuvant chemotherapy demonstrated favorable ORR and MPR with manageable toxicities in patients with head and neck squamous cell carcinoma.
Authors
- Zhiming Li (ORCID: https://orcid.org/0000-0001-9730-9917)
- Xinrui Zhang (ORCID: https://orcid.org/0000-0002-9615-835X)
- Xuekui Liu (ORCID: https://orcid.org/0000-0002-6635-1095)
- Chunyan Chen (ORCID: https://orcid.org/0000-0002-6250-4226)
- Qi Fang (ORCID: https://orcid.org/0009-0001-0407-0140)
- Pengfei Xu (ORCID: https://orcid.org/0000-0002-1174-3630)
- Ruobin Lin
- Lixia Lu (ORCID: https://orcid.org/0000-0002-0549-3786)
- Fei Han (ORCID: https://orcid.org/0000-0002-1598-9048)
- Fei Cao (ORCID: https://orcid.org/0000-0002-9568-2360)
- Jian Zhou (ORCID: https://orcid.org/0000-0002-6868-9866)
- Ke Jiang (ORCID: https://orcid.org/0009-0004-3113-3786)
- Honghong Yan (ORCID: https://orcid.org/0000-0001-9715-3350)
- Di Wu (ORCID: https://orcid.org/0000-0002-6701-9545)
- Zheng Zhao (ORCID: https://orcid.org/0000-0002-9898-0232)
- Yan Li (ORCID: https://orcid.org/0000-0001-6193-5481)
Institutions
- Xinjiang Medical University (CN)
- Sun Yat-sen University (CN)
- Fifth Affiliated Hospital of Xinjiang Medical University (CN)
- Second Affiliated Hospital of Guangzhou Medical University (CN)
- Key Laboratory of Guangdong Province (CN)
- Sun Yat-sen University Cancer Center (CN)
- First Affiliated Hospital of Zhengzhou University (CN)
- State Key Laboratory of Oncology in South China
- Guangzhou Medical University (CN)
Publication Details
- Journal
- Clinical Cancer Research
- Published
- 2025-07-24
- DOI
- https://doi.org/10.1158/1078-0432.ccr-25-1445
- Citations
- 3
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 3.14